Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Review, H2 2018
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Review, H2 2018
SUMMARY
According to the recently published report 'Transient Receptor Potential Cation Channel Subfamily V Member 1 - Pipeline Review, H2 2018'; Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) pipeline Target constitutes close to 37 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes.
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - The transient receptor potential cation channel subfamily V member 1 (TrpV1) is a protein encoded by the TRPV1 gene. It belongs to a sub-family of the transient receptor potential protein group. It mediates proton influx and may be involved in intracellular acidosis in nociceptive neurons.
It is involved in mediation of inflammatory pain and hyperalgesia. It sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. It is activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin. It acts as ionotropic endocannabinoid receptor with central neuromodulatory effects.
The report 'Transient Receptor Potential Cation Channel Subfamily V Member 1 - Pipeline Review, H2 2018' outlays comprehensive information on the Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics development with respective active and dormant or discontinued projects.
Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 8, 5, 10 and 2 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 6 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Dermatology, Metabolic Disorders, Musculoskeletal Disorders, Gastrointestinal, Immunology, Ophthalmology, Genetic Disorders, Genito Urinary System And Sex Hormones, Oncology and Respiratory which include indications Osteoarthritis Pain, Pain, Cancer Pain, Neuropathic Pain (Neuralgia), Muscle Spasm, Muscle Spasticity, Neuro Muscular Disorders, Postherpetic Neuralgia, Pruritus, Congestive Heart Failure (Heart Failure), Diabetic Peripheral Neuropathy, Inflammatory Pain, Alzheimer's Disease, Atherosclerosis, Atopic Dermatitis (Atopic Eczema), Autoimmune Hepatitis, Breast Cancer, Cardiomegaly, Cardiovascular Disease, Cluster Headache Syndrome (Cluster Headache), Cough, Crohn's Disease (Regional Enteritis), Demyelinating Diseases, Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), Infantile Spasm (West Syndrome), Inflammation, Insomnia, Keratoconjunctivitis Sicca (Dry Eye), Lennox-Gastaut Syndrome, Morton Metatarsalgia, Ocular Hypertension, Ocular Pain (Eye Pain), Open-Angle Glaucoma, Post-Operative Pain, Prostate Cancer, Psoriasis, Radiculopathy, Renal Failure, Rosacea, Seborrhea, Squamous Cell Carcinoma, Tuberous Sclerosis, Type 2 Diabetes and Visceral Pain.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Transient Receptor Potential Cation Channel Subfamily V Member 1 - Pipeline Review, H2 2018'; Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) pipeline Target constitutes close to 37 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes.
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - The transient receptor potential cation channel subfamily V member 1 (TrpV1) is a protein encoded by the TRPV1 gene. It belongs to a sub-family of the transient receptor potential protein group. It mediates proton influx and may be involved in intracellular acidosis in nociceptive neurons.
It is involved in mediation of inflammatory pain and hyperalgesia. It sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. It is activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin. It acts as ionotropic endocannabinoid receptor with central neuromodulatory effects.
The report 'Transient Receptor Potential Cation Channel Subfamily V Member 1 - Pipeline Review, H2 2018' outlays comprehensive information on the Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics development with respective active and dormant or discontinued projects.
Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 8, 5, 10 and 2 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 6 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Dermatology, Metabolic Disorders, Musculoskeletal Disorders, Gastrointestinal, Immunology, Ophthalmology, Genetic Disorders, Genito Urinary System And Sex Hormones, Oncology and Respiratory which include indications Osteoarthritis Pain, Pain, Cancer Pain, Neuropathic Pain (Neuralgia), Muscle Spasm, Muscle Spasticity, Neuro Muscular Disorders, Postherpetic Neuralgia, Pruritus, Congestive Heart Failure (Heart Failure), Diabetic Peripheral Neuropathy, Inflammatory Pain, Alzheimer's Disease, Atherosclerosis, Atopic Dermatitis (Atopic Eczema), Autoimmune Hepatitis, Breast Cancer, Cardiomegaly, Cardiovascular Disease, Cluster Headache Syndrome (Cluster Headache), Cough, Crohn's Disease (Regional Enteritis), Demyelinating Diseases, Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), Infantile Spasm (West Syndrome), Inflammation, Insomnia, Keratoconjunctivitis Sicca (Dry Eye), Lennox-Gastaut Syndrome, Morton Metatarsalgia, Ocular Hypertension, Ocular Pain (Eye Pain), Open-Angle Glaucoma, Post-Operative Pain, Prostate Cancer, Psoriasis, Radiculopathy, Renal Failure, Rosacea, Seborrhea, Squamous Cell Carcinoma, Tuberous Sclerosis, Type 2 Diabetes and Visceral Pain.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)
- The report reviews Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Overview
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Development
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Assessment
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Companies Involved in Therapeutics Development
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Drug Profiles
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Dormant Products
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Discontinued Products
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Product Development Milestones
Appendix
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Overview
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Development
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Assessment
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Companies Involved in Therapeutics Development
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Drug Profiles
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Dormant Products
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Discontinued Products
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.1)
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Amgen Inc, H2 2018
Pipeline by Amorepacific Corp, H2 2018
Pipeline by Astellas Pharma Inc, H2 2018
Pipeline by BCN Peptides SA, H2 2018
Pipeline by Centrexion Therapeutics Corp, H2 2018
Pipeline by DoNatur GmbH, H2 2018
Pipeline by Flex Pharma Inc, H2 2018
Pipeline by GrowBLOX Sciences Inc, H2 2018
Pipeline by Grunenthal GmbH, H2 2018
Pipeline by GW Pharmaceuticals Plc, H2 2018
Pipeline by Medifron DBT Co Ltd, H2 2018
Pipeline by Neurim Pharmaceuticals Ltd, H2 2018
Pipeline by Oblique Therapeutics AB, H2 2018
Pipeline by Pila Pharma AB, H2 2018
Pipeline by Sorrento Therapeutics Inc, H2 2018
Pipeline by Sylentis SAU, H2 2018
Pipeline by Vitality Biopharma Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Dormant Products, H2 2018 (Contd.3), H2 2018
Dormant Products, H2 2018 (Contd.4), H2 2018
Dormant Products, H2 2018 (Contd.5), H2 2018
Discontinued Products, H2 2018
Discontinued Products, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.1)
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Amgen Inc, H2 2018
Pipeline by Amorepacific Corp, H2 2018
Pipeline by Astellas Pharma Inc, H2 2018
Pipeline by BCN Peptides SA, H2 2018
Pipeline by Centrexion Therapeutics Corp, H2 2018
Pipeline by DoNatur GmbH, H2 2018
Pipeline by Flex Pharma Inc, H2 2018
Pipeline by GrowBLOX Sciences Inc, H2 2018
Pipeline by Grunenthal GmbH, H2 2018
Pipeline by GW Pharmaceuticals Plc, H2 2018
Pipeline by Medifron DBT Co Ltd, H2 2018
Pipeline by Neurim Pharmaceuticals Ltd, H2 2018
Pipeline by Oblique Therapeutics AB, H2 2018
Pipeline by Pila Pharma AB, H2 2018
Pipeline by Sorrento Therapeutics Inc, H2 2018
Pipeline by Sylentis SAU, H2 2018
Pipeline by Vitality Biopharma Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Dormant Products, H2 2018 (Contd.3), H2 2018
Dormant Products, H2 2018 (Contd.4), H2 2018
Dormant Products, H2 2018 (Contd.5), H2 2018
Discontinued Products, H2 2018
Discontinued Products, H2 2018 (Contd.1), H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Amgen Inc
Amorepacific Corp
Astellas Pharma Inc
BCN Peptides SA
Centrexion Therapeutics Corp
DoNatur GmbH
Flex Pharma Inc
GrowBLOX Sciences Inc
Grunenthal GmbH
GW Pharmaceuticals Plc
Medifron DBT Co Ltd
Neurim Pharmaceuticals Ltd
Oblique Therapeutics AB
Pila Pharma AB
Sorrento Therapeutics Inc
Sylentis SAU
Vitality Biopharma Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Amgen Inc
Amorepacific Corp
Astellas Pharma Inc
BCN Peptides SA
Centrexion Therapeutics Corp
DoNatur GmbH
Flex Pharma Inc
GrowBLOX Sciences Inc
Grunenthal GmbH
GW Pharmaceuticals Plc
Medifron DBT Co Ltd
Neurim Pharmaceuticals Ltd
Oblique Therapeutics AB
Pila Pharma AB
Sorrento Therapeutics Inc
Sylentis SAU
Vitality Biopharma Inc
